Your browser is no longer supported. Please, upgrade your browser.
Settings
APLT Applied Therapeutics, Inc. daily Stock Chart
APLT [NASD]
Applied Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.01 Insider Own- Shs Outstand17.05M Perf Week-12.53%
Market Cap138.12M Forward P/E- EPS next Y- Insider Trans- Shs Float2.46M Perf Month-18.51%
Income- PEG- EPS next Q- Inst Own- Short Float0.00% Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.00 Perf Half Y-
Book/sh-3.55 P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range7.95 - 11.20 Perf YTD-13.83%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-27.67% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low1.89% ATR0.65
Employees4 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)- Volatility9.22% 7.36%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.09 Prev Close8.40
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume97.74K Price8.10
Recom- SMA20-14.13% SMA50-15.53% SMA200-15.53% Volume8,938 Change-3.63%
Jun-10-19Initiated Robert W. Baird Outperform $24
Jun-10-19Initiated Cowen Outperform
Jun-10-19Initiated Citigroup Buy $29
Jun-24-19 07:00AM  Applied Therapeutics Announces Initiation of Phase 1/2 Study of AT-007 in Galactosemia GlobeNewswire
Jun-21-19 07:00AM  Applied Therapeutics Reports First Quarter 2019 Financial Results GlobeNewswire -6.59%
Jun-10-19 10:05AM  Applied Therapeutics Stock Jumps as Analysts Give It a Bullish Welcome Barrons.com +6.45%
Jun-07-19 07:30AM  Applied Therapeutics to Present Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy in Late Breaking Session at the American Diabetes Association 79th Annual Scientific Sessions GlobeNewswire
May-28-19 07:30AM  Applied Therapeutics Announces FDA Orphan Drug Designation for AT-007 in Galactosemia GlobeNewswire
May-24-19 07:00AM  Applied Therapeutics to Present Data at ESC-HF Highlighting AT-001, a Novel, Potent and Selective Aldose Reductase Inhibitor for Treatment of Diabetic Cardiomyopathy GlobeNewswire
May-20-19 10:15PM  Applied Therapeutics Inc (APLT) President and CEO Shoshana Shendelman Bought $1.3 million of Shares GuruFocus.com
May-08-19 07:11AM  Uber in drivers seat as IPO market gears up for busiest week since 2015 MarketWatch
May-07-19 10:46AM  The Applied Therapeutics IPO: What You Need To Know Benzinga
May-04-19 05:25PM  IPO Outlook For The Week: Uber (And 11 Others) Benzinga
Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy. The company's preclinical stage products include AT-001 for acute myocardial infraction; AT-007 for treating galactosemia; AT-003 to treat diabetic retinopathy; and AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.